ContextLogic Inc. Reports Third-Quarter 2024 Financial ResultsOAKLAND, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- ContextLogic Inc. (Nasdaq: LOGC), (“ContextLogic,” the “Company,” “we” or “our”) today reported its financial results for the quarter and nine months ended September 30, 2024.
ContextLogic Inc. Reports Second-Quarter Financial ResultsOAKLAND, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- ContextLogic Inc. (Nasdaq: LOGC), (“ContextLogic,” the “Company,” “we” or “our”) today reported its financial results for the quarter and six months ended June 30, 2024.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Myovant Sciences Ltd. (NYSE - MYOV), ForgeRock, Inc. (NYSE - FORG), SeaSpine Holdings Corporation (Nasdaq - SPNE), LogicBio Therapeutics, Inc. (Nasdaq – LOGC),BALA CYNWYD, Penn., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) ForgeRock, Inc. (NYSE - FORG), SeaSpine Holdings Corporation (Nasdaq - SPNE), LogicBio Therapeutics, Inc. (Nasdaq – LOGC), Coffee Holding Co., Inc. (Nasdaq – JVA)BALA CYNWYD, Pa., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
LOGICBIO® THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LogicBio® Therapeutics, Inc. - LOGC
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of LogicBio® Therapeutics, Inc. (NasdaqGM: LOGC) to Alexion, AstraZeneca Rare Disease. Under the terms of the proposed transaction, shareholders of LogicBio will receive $2.07 for each share of LogicBio that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) CarLotz, Inc. (Nasdaq – LOTZ), LogicBio Therapeutics, Inc. (Nasdaq – LOGC), O2Micro International Limited (Nasdaq – OIIM), Coffee Holding Co., Inc. (Nasdaq – JVA)BALA CYNWYD, Pa., Oct. 07, 2022 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
LOGICBIO® THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LogicBio® Therapeutics, Inc. - LOGC
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of LogicBio® Therapeutics, Inc. (NasdaqGM: LOGC) to Alexion, AstraZeneca Rare Disease. Under the terms of the proposed transaction, shareholders of LogicBio will receive $2.07 for each share of LogicBio that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) LogicBio Therapeutics, Inc. (Nasdaq – LOGC), O2Micro International Limited (Nasdaq – OIIM), Coffee Holding Co., Inc. (Nasdaq – JVA), BTRS Holdings Inc. (Nasdaq –BALA CYNWYD, Pa., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
LOGC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of LogicBio Therapeutics, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of LogicBio Therapeutics, Inc. (
NASDAQLOGC) to AstraZeneca Rare Disease for $2.07 per share is fair to LogicBio shareholders.
Alexion, AstraZeneca Rare Disease to Acquire LogicBio® Therapeutics to Accelerate Growth in Genomic Medicine
Alexion, AstraZeneca Rare Disease, today announced that it has entered a definitive agreement to acquire Lexington, Mass.-based LogicBio® Therapeutics, Inc. (
NASDAQLOGC), a pioneering genomic medicine company. The proposed acquisition aims to rapidly accelerate Alexion’s growth in genomic medicines through LogicBio’s unique technology, experienced rare disease R&D team, and expertise in pre-clinical development.
